Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3).

BMJ Open Diabetes Res Care · 2018 · PMC5841497 · PMID 29527308

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

on the borderline of significanceP=0.06so close (0.05 < p ≤ 0.1)

Proinsulin did not remain a significant predictor in the liraglutide group when adjusting for HbA1c (P=0.11) or mean CGM glucose (P=0.23), although the predictor with treatment interaction was on the borderline of significance (P=0.06 adjusted for HbA1c and P=0.08 adjusted for mean CGM glucose).

also in 75 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.